Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor

Journal of Pharmaceutical Sciences

Volumn 95, Issue 12, 2006, Pages 2722-2729

  Tavornvipas, Sumitra ^a   Hirayama, Fumitoshi ^a,b   Takeda, Seiko ^a   Arima, Hidetoshi ^a   Uekama, Kaneto ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SOJO UNIVERSITY   (Japan)

Author keywords

Aggregation; Basic fibroblast growth factor; Cyclodextrins; Lysozyme; Unfolding

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CYCLODEXTRIN DERIVATIVE; DIMETHYL BETA CYCLODEXTRIN; LYSOZYME; MALTOSE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; ELECTRICITY; ENZYME DENATURATION; HYDROPHILICITY; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN STABILITY; TEMPERATURE MEASUREMENT; THERMAL STIMULATION; THERMODYNAMICS;

EID: 33846185130     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20715     Document Type: Article

References (23)

1. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289:1-30.
2. Stefani M, Dobson CM. 2003. Protein aggregation and aggregate toxicity: News insight into protein folding, misfolding diseases and biological evolutaion. J Mol Med 81:689-699.
3. Dong AC, Prestrelski SJ, Allison SD, Carpenter JF. 1995. Infrared spectroscopic studies of lyophilization-induced and temperature-induced protein aggregation. J Pharm Sci 84:415-424.
4. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897-903.
5. Gass JN, Gunn KE, Sriburiand R, Brewer JW. 2004. Stressed-out B cells? Plasma-cell differentiation and the unfolded protein response. Trends Immunol 25:17-24.
6. Frokjaer S, Otzen DE. 2005. Protein drug stability: A formulation challenge. Nat Rev Drug Discov 4:298-306.
7. Aachmann FL, Otzen DE, Larsen KL, Wimmer R. 2003. Structural background of cyclodextrin-protein interactions. Protein Eng 16:905-912.
8. Brewster ME, Simpkins JW, Hora MS, Sternand WC, Bodor N. 1989. The potential use of cyclodextrins in parenteral formulations. J Parenter Sci Technol 43:231-240.
9. Yamamoto M, Aritomi H, Irie T, Hirayama F, Uekama K. 1991. Biopharmaceutical evaluation of maltosyl-β-cyclodextrin as a parenteral drug carrier. STP Pharma Sci 1:397-402.
10. Tavornvipas S, Hirayama F, Arima H, Uekama K, Ishiguro T, Oka M, Hamayasu K, Hashimoto H. 2002. 6-O-α-(4-O-α-D-Glucuronyl)-D-glucosyl-β- cyclodextrin: Solubilizing ability and some cellular effects. Int J Pharm 249:199-209.
11. Sluzky V, Shahrokh Z, Stratton PA, Eberlein GA, Wang J. 1994. Chromatographic methods for quantitation of native, denatured and aggregated bFGF in solution formulations. Pharm Res 11:485-490.
12. Dong X, Shi J, Sun Y. 2002. Cooperative effects of artificial chaperones and guanidium chloride on lysozyme renaturation at high concentrations. Biotechnol Prog 18:663-665.
13. Tavornvipas S, Tajiri S, Hirayama F, Arima H, Uekama K. 2004. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm Res 21:2369-2376.
14. Jelesarov I, Bosshard HR. 1999. Isothermal titration calorimetry and differential scanning calorimetry as complementary tools to investigate the energetics of biomolecular recognition. J Mol Recognit 12:3-18.
15. Cooper A. 1992. Effect of cyclodextrins on the thermal stability of globular proteins. J Am Chem Soc 114:9208-9209.
16. Arakawa T, Timasheff SN. 1992. Stabilization of protein structure by Sugars. Biochemistry 21:6536-6544.
17. Arakawa T, Tsumoto K. 2003. The effects of arginine on refolding of aggregated proteins: Not facilitate refolding, but suppress aggregation. Biochem Biophys Res Comm 304:148-152.
18. Kajio T, Kawahara K, Kato K. 1992. Stabilization of basic fibroblast growth factor with dextran sulfate. FEBS Lett 306:243-246.
19. Fukunaga K, Hijikata S, Ishimura K, Sonoda R, Irie T, Uekama K. 1994. Aluminium β-cyclodextrin sulphate as a stabilizer and sustained-release carrier for basic fibroblast growth factor. J Pharm Pharmacol 46:168-171.
20. Vemuri S, Beylin I, Sluzky V, Stratton PA, Eberlein GA, Wang YJ. 1994. The stability of bFGF against thermal denaturation. J Pharm Pharmacol 46:481-486.
21. Gospodarowicz D, Cheng J. 1986. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128:475-484.
22. Wang YJ, Shahrokh A, Vemuri S, Eberlein G, Beylin I, Busch M. 1996. Characterization, stability and formulation of basic fibroblast growth factor. In: Pearlman R, Wang YJ, editors. Stability and characterization of protein and peptide drugs. New York: Plenum Press, pp 141-180.
23. Copeland RA, Ji H, Halfpenny AJ, Williams RW, Thompson KC, Herber WK, Thomas KA, Bruner MW, Ryan JA, Marquis-Omer D, Sanyal G, Sitrin RD, Yamazaki S, Middaugh CR. 1991. The structure of human acidic fibroblast growth factor and its interaction with heparin. Arch Biochem Biophys 239:53-61.